Since then, numerous reports, of increasing frequency, have characterised DMD gene mutations and/or expression changes associated with the development, progression and/or survival of patients with a wide range of cancers including sarcomas, carcinomas, melanomas, lymphomas and leukaemia’s, as well as brain tumours [18–26]. The gene discussed is DMD; the disease is brain neoplasm.